Clinical Trial: A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07900516) titled 'A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.' on Aug. 05.

Brief Summary: To explore the efficacy and safety of Culmerciclib combined with chemotherapy as neoadjuvant therapy for HR+/HER2- breast cancer patients who are insensitive to neoadjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) chemotherapy.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: Kumoxili

Kumoxili 180mg po qd

DRUG: Docetaxel

Docetaxel 75mg/m2 iv q3w

DRUG: Epirubicin

Epirubic...